Hos patienter med mild til moderat leverinsufficiens er biotilgængeligheden af zaleplon forøget på grund af nedsat clearance, og dosis skal derfor modificeres til disse patienter.
In patients with mild to moderate hepatic insufficiency, the bioavailability of zaleplon is increased because of reduced clearance, and the dose will therefore need to be modified in these patients.